Dexrazoxane Shows Long-Term Heart Protection
Quick Facts
How Does Dexrazoxane Protect the Heart During Chemotherapy?
Anthracyclines such as doxorubicin and daunorubicin are effective treatments for several childhood cancers, but they can damage cardiomyocytes, the muscle cells responsible for pumping blood. Injury may begin during treatment yet remain clinically silent for years before contributing to reduced heart function, cardiomyopathy or heart failure.
Dexrazoxane is administered around the time of anthracycline treatment to reduce this injury. Its protective activity involves interactions with iron-dependent oxidative damage and topoisomerase II pathways implicated in anthracycline cardiotoxicity. It is a preventive medicine rather than a treatment for established heart failure, and dosing must be coordinated with the child’s chemotherapy regimen.
What Does the Long-Term Evidence Mean for Childhood Cancer Care?
The newly reported research found evidence of less cardiac damage among pediatric cancer survivors who had received dexrazoxane, with follow-up extending 15 years or longer after treatment. This long observation period matters because anthracycline-related cardiomyopathy can emerge gradually, after patients have completed cancer therapy and transitioned to adult care.
The results strengthen the case for incorporating cardioprotection into treatment planning when anthracyclines are necessary. Available pediatric follow-up has generally been reassuring about cancer outcomes, although oncologists must still consider the malignancy, chemotherapy protocol, cumulative anthracycline exposure and each patient’s cardiac risk before recommending dexrazoxane.
Do Survivors Still Need Heart Screening After Receiving Dexrazoxane?
The Children’s Oncology Group recommends risk-based follow-up for survivors exposed to potentially cardiotoxic cancer treatments. Monitoring may include medical history, blood-pressure assessment and echocardiography at intervals determined by treatment exposure and individual risk factors. Survivors should keep a treatment summary documenting the anthracycline received, cumulative dose and any cardioprotective therapy.
New breathlessness, chest discomfort, fainting, palpitations, swelling or an unexplained decline in exercise tolerance warrants medical assessment. Maintaining healthy blood pressure, avoiding tobacco, staying physically active as medically appropriate and managing cholesterol or diabetes can help reduce additional cardiovascular stress, but these measures do not replace recommended surveillance.
Frequently Asked Questions
No. Its use depends on the cancer protocol, expected anthracycline exposure, cardiac risk and specialist judgment. Families should discuss potential benefits and uncertainties with the pediatric oncology team.
Dexrazoxane is primarily used to prevent or reduce injury during anthracycline treatment. Established cardiomyopathy requires evaluation and management by oncology and cardiology specialists.
Cardiac injury can become apparent during treatment or many years later. That long latency is why risk-based survivorship care remains important even when a person feels well.
References
- Medical Xpress. Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends. 2026.
- U.S. Food and Drug Administration. Zinecard (dexrazoxane for injection) prescribing information.
- National Cancer Institute. Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version.
- Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers.